<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996605</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00025901</org_study_id>
    <nct_id>NCT01996605</nct_id>
  </id_info>
  <brief_title>Efficacy of Spinal Oxytocin in Healthy Volunteers</brief_title>
  <official_title>Efficacy of Intrathecal Oxytocin in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of intrathecal oxytocin on areas and
      intensity of hyperalgesia and allodynia induced by topical capsaicin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: There is a strong experimental basis to support the study of oxytocin by the spinal
      route for analgesia in humans. Oxytocin containing cells in the dorsal parvocellular division
      of the paraventricular nucleus (PVN) project to the spinal cord (1). Noxious stimulation
      activates these cells via the A1 noradrenergic relay in the pons (2) and produces analgesia
      by spinal release of oxytocin, since intrathecal injection of an oxytocin receptor antagonist
      worsens pain behaviors from peripheral inflammation (3). Direct electrical stimulation of the
      PVN reduces dorsal horn neuronal responses to noxious stimulation, and this is blocked by
      administration of sequestering antibody for oxytocin (4). Similarly, direct electrical
      stimulation of the PVN reduces behavioral sensitivity in a model of chronic neuropathic pain,
      and this effect is blocked by an oxytocin receptor antagonist (5). Intrathecal injection of
      oxytocin in normal rats reduces dorsal horn neuronal responses to noxious stimuli (6) as well
      as behavioral responses to noxious thermal (3), mechanical (3), and chemical (7) stimuli.
      Finally, intrathecal injection of oxytocin in rat models of chronic pain also reduces dorsal
      horn neuronal responses to sensory stimulation (6) as well as behavioral responses to thermal
      (5) and mechanical (7) stimuli.

      Rationale: We anticipate that oxytocin will be effective after spinal injection in humans
      against chemical induced hypersensitivity states.

      Objectives: Determine the effect of intrathecal oxytocin on areas and intensity of
      hyperalgesia and allodynia induced by topical capsaicin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperalgesia</measure>
    <time_frame>105 minutes</time_frame>
    <description>The area of hyperalgesia after the first skin heating following topical capsaicin.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>Oxytocin 15 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 15 mcg injected spinally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin 150 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 150 mcg injected spinally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preservative free normal saline injected spinally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 15 mcg</intervention_name>
    <description>Oxytocin 15 mcg will be administered spinally</description>
    <arm_group_label>Oxytocin 15 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin 150 mcg</intervention_name>
    <description>Oxytocin 150 mcg will be administered spinally</description>
    <arm_group_label>Oxytocin 150 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo will be administered spinally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  weight &lt; 240 pounds

          -  American Society of Anesthesiology Category 1 or 2

        Exclusion Criteria:

          -  allergy to oxytocin or lidocaine

          -  allergy to chilli peppers

          -  Females: active gynecological disease such as uterine fibroids or ongoing bleeding

          -  Pregnancy or currently breastfeeding

          -  Females that have delivered a baby within 2 years of study

          -  Taking prescription medications (exception: oral birth control medication)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Eisenach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Curry, RN</last_name>
      <phone>336-716-4294</phone>
      <email>recurry@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>James C Eisenach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

